What’s all this talk of cancer vaccines? We find out how they work – and how mRNA has boosted the field – with the help of five experts.

RNA sequence design is emerging as a path to transform the economics and methodologies of RNA as a drug modality.

Katalin Karikó and Drew Weissman win prestigious prize for persevering in a field that many ignored.

Manufacturers have a unique opportunity to take advantage of the cost and time advantages associated with Oligo(dT) – the adoption process is simple.

With mRNA offering more straightforward development and manufacturing processes, are the days of traditional vaccine modalities numbered?

Though key hurdles remain, there is huge potential for mRNA-based therapeutics to tackle areas of unmet need.

Cancer vaccines are compelling but there are challenges that must be faced. Experts give their view.

How a new collaboration looks to improve analytical testing for mRNA products.

mRNA therapeutics are a hot development trend, but with expertise and experience in short supply, who are the unsung heroes?